Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Ankara University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Turkish Society of Hematology
Information provided by:
Ankara University
ClinicalTrials.gov Identifier:
NCT01096875
First received: March 16, 2010
Last updated: April 13, 2010
Last verified: November 2009
  Purpose

Experimental data have demonstrated favourable effects of statins on endothelial progenitor cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present prospective randomized controlled trial is to determine the effects of aggressive atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.


Condition Intervention Phase
Coronary Artery Bypass Surgery
Elective Surgical Procedure
Drug: Atorvastatin
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Ankara University:

Primary Outcome Measures:
  • Endothelial Progenitor Cell Count [ Time Frame: Postoperative 6th hours ] [ Designated as safety issue: No ]
    Endothelial Progenitor Cell (EPC) Count


Secondary Outcome Measures:
  • Clinical events [ Time Frame: Postoperatively 30 days ] [ Designated as safety issue: No ]
    1. Increase in left ventricular ejection fraction [Time Frame:30 days postoperatively]
    2. Major adverse cardiovascular events [Time Frame:30 days postoperatively]
    3. hsCRP [Time Frame: Postoperative 24 hours, 5 days]


Estimated Enrollment: 60
Study Start Date: February 2010
Estimated Study Completion Date: October 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Atorvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug: Atorvastatin
40mg/day once daily for two weeks prior to surgery
Other Name: Ator
Placebo Comparator: Placebo
Atorvastatin like pill
Drug: Placebo
1tb/day once daily for two weeks prior to surgery
Other Name: Placebo tablets matched to atorvastatin

Detailed Description:

Endothelial progenitor cells, a subgroup of hematopoietic stem cells have a significant role in vascular homeostasis. In animal models of ischemia, endothelial progenitor cells are rapidly incorporated into sites of neovascularization, have the potential to induce and augment vasculogenesis/ angiogenesis, prevent cardiomyocyte apoptosis in peri-infarct regions, and reduce adverse remodeling. Treatment with atorvastatin has been shown to increase endothelial progenitor cell count in patients with coronary artery disease. Therefore, we will investigate whether atorvastatin augments the number of endothelial progenitor cells after cardiopulmonary bypass in patients undergoing coronary artery bypass surgery (CABG). Thus, we conducted a randomized double-blind, placebo-controlled, 2-way parallel trial in 60 patients undergoing coronary artery bypass surgery. Patients will receive either 2-week treatment with atorvastatin or placebo prior to surgery. Endothelial progenitor cells will be quantitated by flow cytometric phenotyping obtained from peripheral blood samples. In addition, cardiac markers (CK-MB mass, cardiac troponin-I), biochemical profile, liver function tests, high sensitive C-reactive protein (hsCRP) and coagulation profile will be determined at 4 time points: 1) preoperatively (baseline); 2) 6 hours after the end of cardiopulmonary bypass; 3) 24 hours after surgery; 4) 5th days postoperatively. Clinical, operative characteristics, cardiac markers, high sensitive C-reactive protein and endothelial progenitor cell count will be compared between the groups. Adverse outcomes will also be noted and reported.

  Eligibility

Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing elective isolated coronary artery bypass surgery with on-pump technique
  • Written informed consent

Exclusion Criteria:

  • Concomitant valve or aortic surgery
  • Left ventricular aneurysm repair
  • Re-operation
  • Emergency surgery
  • History of myocardial infarction within less than 4 weeks
  • Hepatic impairment
  • Chronic renal impairment
  • Drug related side effects (allergy or hypersensitivity)
  • Familial Hyperlipidemia
  • Autoimmune conditions which require steroids
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01096875

Contacts
Contact: RUCHAN A AKAR, Assoc.Prof. +905336460684 akarruchan@gmail.com
Contact: CAGDAS BARAN, MD +905334697923 cagdasbaran@gmail.com

Locations
Turkey
Ankara University Medical Faculty, Department of Cardiovascular Surgery Recruiting
Ankara, Cebeci, Turkey, 06340
Contact: AKAR RUCHAN, Assoc.Prof.    +905336460684    akarruchan@gmail.com   
Contact: CAGDAS BARAN, MD    +905334697923    cagdasbaran@gmail.com   
Principal Investigator: RUCHAN AKAR, Assoc.Prof.         
Principal Investigator: ONDER ASLAN, Prof.         
Sub-Investigator: CAGDAS BARAN, MD         
Sub-Investigator: SERKAN DURDU, MD         
Sub-Investigator: KLARA DALVA, MD         
Sub-Investigator: CAGIN ZAIM, MD         
Sub-Investigator: UMIT OZYURDA, Prof.         
Sponsors and Collaborators
Ankara University
Turkish Society of Hematology
Investigators
Study Director: RUCHAN AKAR, Assoc. Prof. Ankara University Medical Faculty, Department of Cardiovascular Surgery Ankara, Turkey, 06340
Study Chair: ONDER ASLAN, Prof. Ankara University Medical Faculty, Department of Hematology Ankara, Turkey
  More Information

No publications provided by Ankara University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Assoc. Prof. A. Ruchan Akar / Ankara University, Ankara University, Department of Cardiovascular Surgery
ClinicalTrials.gov Identifier: NCT01096875     History of Changes
Other Study ID Numbers: UMT0043
Study First Received: March 16, 2010
Last Updated: April 13, 2010
Health Authority: Turkey: Ministry of Health

Keywords provided by Ankara University:
Endothelial progenitor cells
Atorvastatin
Coronary surgery

Additional relevant MeSH terms:
Atorvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 16, 2014